EP1790351A4 - Permucosal composition and method of improving permucosal absorption - Google Patents

Permucosal composition and method of improving permucosal absorption

Info

Publication number
EP1790351A4
EP1790351A4 EP05782391A EP05782391A EP1790351A4 EP 1790351 A4 EP1790351 A4 EP 1790351A4 EP 05782391 A EP05782391 A EP 05782391A EP 05782391 A EP05782391 A EP 05782391A EP 1790351 A4 EP1790351 A4 EP 1790351A4
Authority
EP
European Patent Office
Prior art keywords
permucosal
improving
composition
absorption
permucosal absorption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP05782391A
Other languages
German (de)
French (fr)
Other versions
EP1790351A8 (en
EP1790351A1 (en
Inventor
Akira Yamamoto
Keigo Yamada
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Otsuka Pharmaceutical Co Ltd
Original Assignee
Otsuka Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharmaceutical Co Ltd filed Critical Otsuka Pharmaceutical Co Ltd
Publication of EP1790351A1 publication Critical patent/EP1790351A1/en
Publication of EP1790351A8 publication Critical patent/EP1790351A8/en
Publication of EP1790351A4 publication Critical patent/EP1790351A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
EP05782391A 2004-09-15 2005-09-12 Permucosal composition and method of improving permucosal absorption Withdrawn EP1790351A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004268891 2004-09-15
PCT/JP2005/016739 WO2006030730A1 (en) 2004-09-15 2005-09-12 Permucosal composition and method of improving permucosal absorption

Publications (3)

Publication Number Publication Date
EP1790351A1 EP1790351A1 (en) 2007-05-30
EP1790351A8 EP1790351A8 (en) 2007-10-10
EP1790351A4 true EP1790351A4 (en) 2009-11-04

Family

ID=36059983

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05782391A Withdrawn EP1790351A4 (en) 2004-09-15 2005-09-12 Permucosal composition and method of improving permucosal absorption

Country Status (13)

Country Link
US (1) US20080075691A1 (en)
EP (1) EP1790351A4 (en)
JP (1) JPWO2006030730A1 (en)
KR (1) KR20070057932A (en)
CN (1) CN101018560A (en)
AR (1) AR050937A1 (en)
AU (1) AU2005283512A1 (en)
BR (1) BRPI0515301A (en)
CA (1) CA2577336A1 (en)
MX (1) MX2007003062A (en)
RU (1) RU2007114068A (en)
TW (1) TW200612975A (en)
WO (1) WO2006030730A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA100375C2 (en) * 2007-03-30 2012-12-25 Хірофумі Такеуті Transpulmonary liposome for controlling drug arrival
CN101959532B (en) * 2008-02-28 2013-02-27 东丽株式会社 Pharmaceutical composition for transnasal administration
WO2011142484A1 (en) * 2010-05-14 2011-11-17 株式会社日本触媒 Therapeutic agent for viral infections comprising polyalkyleneimine

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971956A (en) * 1984-11-29 1990-11-20 Ihara Chemical Industry Co., Ltd. Immunopotentiating agents and method
WO1998022136A2 (en) * 1996-11-19 1998-05-28 Roche Diagnostics Gmbh Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
US6333304B1 (en) * 1999-04-20 2001-12-25 Teresa K. Bath Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
WO2002034287A2 (en) * 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
DE102004040243A1 (en) * 2003-08-22 2005-03-17 Heppe, Katja, Dipl.-Biotechnol. Transport system for overcoming the blood-brain barrier, useful for the treatment and diagnosis of brain-specific diseases, comprises chitin, chitosan, chitosan oligosaccharides or glucosamine
WO2005079749A2 (en) * 2004-02-21 2005-09-01 Archimedes Development Limited Chitosan containing solution

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9525083D0 (en) * 1995-12-07 1996-02-07 Danbiosyst Uk Vaccine compositions
US6184037B1 (en) * 1996-05-17 2001-02-06 Genemedicine, Inc. Chitosan related compositions and methods for delivery of nucleic acids and oligonucleotides into a cell
JPH11116499A (en) * 1997-10-16 1999-04-27 Asahi Chem Ind Co Ltd Nanosphere for oral administration containing bioactive peptide
GB9725084D0 (en) * 1997-11-28 1998-01-28 Medeva Europ Ltd Vaccine compositions
JP3041799B1 (en) * 1998-09-29 2000-05-15 株式会社微生物化学研究所 Novel adjuvant and vaccine using the same
IL131074A0 (en) * 1999-07-23 2001-03-19 Polygene Ltd A biodegradable polycation composition for delivery of an anionic macromolecule
US6773723B1 (en) * 2000-08-30 2004-08-10 Depuy Acromed, Inc. Collagen/polysaccharide bilayer matrix
NO317654B1 (en) * 2002-05-03 2004-11-29 Stiftelsen Biopolymer Formulation containing a nucleic acid and a chitosan, process for preparing the formulation, and applications thereof.

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4971956A (en) * 1984-11-29 1990-11-20 Ihara Chemical Industry Co., Ltd. Immunopotentiating agents and method
WO1998022136A2 (en) * 1996-11-19 1998-05-28 Roche Diagnostics Gmbh Stable lyophilized pharmaceutical substances from monoclonal or polyclonal antibodies
US6333304B1 (en) * 1999-04-20 2001-12-25 Teresa K. Bath Therapeutic compositions containing glucosamine, collagen and a bioflavanol for repair and maintenance of connective tissue
WO2002034287A2 (en) * 2000-10-27 2002-05-02 Pharmexa A/S Therapeutic vaccine formulations containing chitosan
DE102004040243A1 (en) * 2003-08-22 2005-03-17 Heppe, Katja, Dipl.-Biotechnol. Transport system for overcoming the blood-brain barrier, useful for the treatment and diagnosis of brain-specific diseases, comprises chitin, chitosan, chitosan oligosaccharides or glucosamine
WO2005079749A2 (en) * 2004-02-21 2005-09-01 Archimedes Development Limited Chitosan containing solution

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ASPDEN T ET AL: "CHITOSAN AS A NASAL DELIVERY SYSTEM: THE EFFECT OF CHITOSAN SOLUTIONS ON INVITRO AND IN VIVO MUCOCILIARY TRANSPORT RATES IN HUMAN TURBINATES AND VOLUNTEERS", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 86, no. 4, 1 April 1997 (1997-04-01), pages 509 - 513, XP000683471, ISSN: 0022-3549 *
KOPING-HOGGARD M ET AL: "Improved chitosan-mediated gene delivery based on easily dissociated chitosan polyplexes of highly defined chitosan oligomers", GENE THERAPY, MACMILLAN PRESS LTD., BASINGSTOKE, GB, vol. 11, no. 19, 22 July 2004 (2004-07-22), pages 1441 - 1452, XP002471182, ISSN: 0969-7128 *
See also references of WO2006030730A1 *
SEO W-G ET AL: "SYNERGISTIC COOPERATION BETWEEN WATER-SOLUBLE CHITOSAN OLIGOMERS AND INTERFERON-GAMMA FOR INDUCTION OF NITRIC OXIDE SYNTHESIS AND TUMORICIDAL ACTIVITY IN MURINE PERITONEAL MACROPHAGES", CANCER LETTERS, NEW YORK, NY, US, vol. 159, no. 2, 1 January 2000 (2000-01-01), pages 189 - 195, XP001199459, ISSN: 0304-3835 *
THANOU M ET AL: "Oral drug absorption enhancement by chitosan and its derivatives.", ADVANCED DRUG DELIVERY REVIEWS 5 NOV 2001, vol. 52, no. 2, 5 November 2001 (2001-11-05), pages 117 - 126, XP002546628, ISSN: 0169-409X *

Also Published As

Publication number Publication date
BRPI0515301A (en) 2008-07-15
AU2005283512A1 (en) 2006-03-23
WO2006030730A1 (en) 2006-03-23
AR050937A1 (en) 2006-12-06
CN101018560A (en) 2007-08-15
US20080075691A1 (en) 2008-03-27
TW200612975A (en) 2006-05-01
CA2577336A1 (en) 2006-03-23
JPWO2006030730A1 (en) 2008-05-15
EP1790351A8 (en) 2007-10-10
MX2007003062A (en) 2007-05-21
KR20070057932A (en) 2007-06-07
TWI291874B (en) 2008-01-01
EP1790351A1 (en) 2007-05-30
RU2007114068A (en) 2008-10-27

Similar Documents

Publication Publication Date Title
GB2414666B (en) Sanitizing composition and method of preparation
IL177793A0 (en) Method and composition for burned skin
EP1765260A4 (en) Sanitizing composition and method of preparation
EP1827419A4 (en) Methods and compositions for enhancing iron absorption
HK1101347A1 (en) Fasudil-containing preparation and method of improving stability thereof
IL183709A0 (en) Compositions and methods for treating conditions of the nail unit
IL182337A0 (en) Method and composition for enhancing anti-angiogenic therapy
EP1786265A4 (en) Novel compositions and methods of treatment
EP1937075A4 (en) Synergistic composition and method of use
HK1175117A1 (en) Composition and method for the treatment of asthma symptoms
EP1765373A4 (en) Ozonidzed pharmaceutical composition and method
GB0416252D0 (en) Cosmetic method and composition
ZA200605722B (en) Composition and method
GB0608398D0 (en) Pharmaceutical composition and method of using same
HK1109576A1 (en) Aequorin-containing compositions and methods of using same
EP1684771A4 (en) Composition and method
EP1824462A4 (en) Composition and method for the treatment of tauopathies
GB0520930D0 (en) Composition and method of use
EP1749090A4 (en) Cell therapy formulation method and composition
EP1790351A4 (en) Permucosal composition and method of improving permucosal absorption
EP1812032A4 (en) Tissue factor composition and methods
GB0403696D0 (en) Process and composition
GB0419175D0 (en) Method of treatment and compositions
GB0608399D0 (en) Pharmaceutical composition and method of using same
GB0417415D0 (en) Composition and method

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070315

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: OTSUKA PHARMACEUTICAL CO., LTD.

RIN1 Information on inventor provided before grant (corrected)

Inventor name: YAMAMOTO, AKIRA

Inventor name: YAMADA, KEIGOC

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20091007

17Q First examination report despatched

Effective date: 20100203

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20120331